Diversified Trust Co decreased its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 10.7% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 5,000 shares of the company’s stock after selling 600 shares during the period. Diversified Trust Co’s holdings in Omnicell were worth $216,000 as of its most recent SEC filing.
Other large investors also recently made changes to their positions in the company. Russell Investments Group Ltd. bought a new stake in shares of Omnicell during the fourth quarter worth $1,628,000. Bank of America Corp DE boosted its stake in shares of Omnicell by 79.7% in the first quarter. Bank of America Corp DE now owns 202,466 shares of the company’s stock worth $8,231,000 after buying an additional 89,817 shares in the last quarter. First National Bank of Omaha bought a new stake in shares of Omnicell during the first quarter worth $865,000. Parametric Portfolio Associates LLC boosted its stake in shares of Omnicell by 4.9% in the first quarter. Parametric Portfolio Associates LLC now owns 145,279 shares of the company’s stock worth $5,906,000 after buying an additional 6,786 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of Omnicell during the fourth quarter worth $788,000. Institutional investors and hedge funds own 96.35% of the company’s stock.
Shares of Omnicell, Inc. (OMCL) traded down 0.30% on Wednesday, hitting $50.60. 201,719 shares of the company were exchanged. Omnicell, Inc. has a 52-week low of $30.35 and a 52-week high of $51.97. The firm’s market cap is $1.90 billion. The company has a 50-day moving average price of $45.95 and a 200 day moving average price of $41.54.
Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, July 27th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.02. The firm had revenue of $180.90 million during the quarter, compared to the consensus estimate of $174.08 million. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. The company’s revenue was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.38 EPS. Analysts predict that Omnicell, Inc. will post $1.31 EPS for the current fiscal year.
OMCL has been the subject of a number of recent analyst reports. Zacks Investment Research cut shares of Omnicell from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th. ValuEngine upgraded shares of Omnicell from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. BidaskClub upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 10th. CIBC lifted their price target on shares of Omnicell from $43.00 to $53.00 and gave the company an “outperform” rating in a research report on Wednesday, April 26th. Finally, Piper Jaffray Companies reiterated a “hold” rating and set a $40.00 price target on shares of Omnicell in a research report on Sunday, July 30th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $49.00.
In related news, VP Peter J. Kuipers sold 18,054 shares of the stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $50.31, for a total transaction of $908,296.74. Following the completion of the sale, the vice president now owns 44,236 shares of the company’s stock, valued at approximately $2,225,513.16. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Robin Gene Seim sold 15,109 shares of the stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $50.86, for a total transaction of $768,443.74. Following the sale, the executive vice president now directly owns 58,144 shares of the company’s stock, valued at approximately $2,957,203.84. The disclosure for this sale can be found here. In the last three months, insiders have sold 214,932 shares of company stock valued at $10,069,835. Corporate insiders own 3.77% of the company’s stock.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with our FREE daily email newsletter.